Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 14/20 | 0.79 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.58 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6715646 | 0.89 | ADORA3 (0.80) | ADORA3ADORA1MAPTTHRBADORA2A | |
| SCHEMBL6715604 | 0.89 | ADORA3 (1.00) | ADORA3ADORA1ADORA2A | |
| SCHEMBL6723302 | 0.88 | ADORA3 (0.94) | ADORA3ADORA1ADORA2A | |
| SCHEMBL6723204 | 0.87 | ADORA3 (0.77) | ADORA3ADORA1MAPTADORA2AHSP90AB1 | |
| SCHEMBL6713872 | 0.85 | ADORA3 (0.78) | ADORA3ADORA1MAPTADORA2APOLB | |
| SCHEMBL6717315 | 0.85 | ADORA3 (0.78) | ADORA3ADORA1MAPTADORA2APOLB | |
| SCHEMBL6713745 | 0.85 | ADORA3 (0.78) | ADORA3ADORA1MAPTADORA2A | |
| SCHEMBL6715672 | 0.85 | ADORA3 (0.78) | ADORA3ADORA1MAPTADORA2AHSP90AB1 | |
| SCHEMBL22979306 | 0.82 | ADORA3 (0.65) | ADORA3ADORA1MAPTTHRBADORA2A | |
| SCHEMBL22988304 | 0.82 | ADORA3 (0.65) | ADORA3ADORA1MAPTTHRBADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142952-A1 | Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-07-22 | — | — | US | disclosed |
| EP-1364953-A1 | TRIAZOLOQUINAZOLINE AND PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES, MEDICINAL COMPOSITIONS, ADENOSINE A3 RECEPTOR AFFINITY AGENTS, OCULAR TENSION LOWERING AGENTS, PREPARATIONS FOR PREVENTING AND TREATING GLAUCOMA AND METHOD OF LOWERING OCULAR TENSION | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2003-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142952-A1 | Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension | ADORA3, ADORA1, ADORA2A | ADORA3 1/4885ADORA1 2/4885MAPT 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.